secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K/A
Filed at:   2026-02-23T23:59:59+00:00
Accession:  0001683168-26-001263
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.55
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health files Scorpius audited financials; FY2024 net loss $32.8M on $6.2M revenue
--------------------------------------------------------------------------------

- Scorpius FY2024 revenue $6.24M, net loss $32.8M; auditor BDO flags going-concern doubt due to recurring losses.
- Scorpius total assets $39.2M, total liabilities $37.5M, stockholders' equity $1.7M at Dec 31, 2024.
- Tivic sub Velocity Bioworks acquired all Scorpius assets on Dec 9, 2025, assuming no pre-closing liabilities.
- Pro forma combined financials filed for Sep 30, 2025 and FY2024; combined company impact not quantified.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000168316826001263/0001683168-26-001263-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000168316826001263/tivic_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-001263

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer